Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International ConferenceGlobeNewsWire • 03/27/24
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary FibrosisGlobeNewsWire • 03/12/24
Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to DeclineZacks Investment Research • 03/07/24
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial ResultsGlobeNewsWire • 02/27/24
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver FibrosisGlobeNewsWire • 02/04/24
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/24
Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing CholangitisGlobeNewsWire • 11/13/23
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/09/23
Is a Surprise Coming for Pliant Therapeutics (PLRX) This Earnings Season?Zacks Investment Research • 11/09/23
Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 11/07/23
Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1GlobeNewsWire • 11/06/23
Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of CancerGlobeNewsWire • 10/31/23
Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023GlobeNewsWire • 10/19/23
Pliant Therapeutics, Inc. (PLRX) Soars 14.3%: Is Further Upside Left in the Stock?Zacks Investment Research • 09/27/23
Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trialMarket Watch • 09/26/23
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver FibrosisGlobeNewsWire • 09/26/23
Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing CholangitisGlobeNewsWire • 09/25/23